Medication info
Nexrazole 20mg (Esomeprazole Magnesium Trihydrate)

Nexrazole 20mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.3mg / 1 tablet
Manufacturer / importer
Bionex Co., Ltd.
Appearance
Pale pink, round film-coated tablet
Packaging
28 tablets (14 tablets/PTP*2)
Approval status
Active

MFDS item code 201403798 · Approved 2014.08.18 · Insurance code 643103840

Summary

Main use
Treatment of acid-related disorders and prevention of rebleeding; Helicobacter pylori eradication; treatment and prevention of gastrointestinal disorders caused by anti-inflammatory drugs
Who uses it
Adults · Children
Adult dosage
1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent episodes can be controlled by administering 20 mg once daily. · In adults, 20 mg can be administered once daily as needed. As-needed administration is not recommended to control subsequent symptoms in patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective and selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials exceeding 4 weeks have not been conducted. 4) Patients requiring ongoing nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment duration is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should be continued while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into two doses. 6) Maintenance therapy following induction of prevention of recurrent bleeding from gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of recurrent bleeding from gastric or duodenal ulcers with intravenous administration. 4. Renal impairment: No dosage adjustment is necessary. Use with caution because experience with administration to patients with severe renal impairment is limited. 5. Hepatic impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. 6. Older adults: No dosage adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms have resolved, control any subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended to control recurring symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age: There is no experience with administering this medicine to children under 12 years of age.

Ingredients

Manufacturer
Bionex Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders and prevention of rebleeding; Helicobacter pylori eradication; treatment and prevention of gastrointestinal disorders caused by anti-inflammatory drugs

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication is used to treat gastroesophageal reflux disease and erosive esophagitis, and can be taken for long periods to prevent recurrence. It is also used in combination with antibiotics to treat duodenal and peptic ulcers associated with Helicobacter pylori infection. Additionally, it helps in the short-term treatment of upper gastrointestinal symptoms that may occur with non-steroidal anti-inflammatory drugs (NSAIDs), and is effective for the treatment and prevention of gastric ulcers if long-term administration is needed. It is effective for Zollinger-Ellison syndrome and is also used as maintenance therapy to prevent rebleeding from gastric or duodenal ulcers. Overall, it is widely used for the treatment of various symptoms and disorders related to gastrointestinal diseases.

Dosage and Administration

Adult dosage

1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent episodes can be controlled by administering 20 mg once daily. · In adults, 20 mg can be administered once daily as needed. As-needed administration is not recommended to control subsequent symptoms in patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective and selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials exceeding 4 weeks have not been conducted. 4) Patients requiring ongoing nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment duration is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should subsequently be adjusted for each patient, and treatment should be continued while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into two doses. 6) Maintenance therapy following induction of prevention of recurrent bleeding from gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of recurrent bleeding from gastric or duodenal ulcers with intravenous administration. 4. Renal impairment: No dosage adjustment is necessary. Use with caution because experience with administration to patients with severe renal impairment is limited. 5. Hepatic impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. 6. Older adults: No dosage adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms have resolved, control any subsequent symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended to control recurring symptoms in patients at high risk of developing gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age: There is no experience with administering this medicine to children under 12 years of age.

Precautions

This medication should not be used in certain patients. Individuals who have allergies or have experienced hypersensitivity reactions to this medication, its ingredients, or benzimidazole derivatives should not take it. Additionally, individuals allergic to amoxicillin or clarithromycin should avoid this medication when combined with it for the eradication of Helicobacter pylori. It is also recommended not to use this medication in patients taking certain heart-related medications, nursing women, or those with a history of myocardial infarction. This medication contains dye number 4, so individuals with allergic reactions or hypersensitivity to this dye should use it with caution. During treatment, various adverse reactions can occur, including headache, abdominal pain, diarrhea, skin rash, muscle pain, and dizziness. Particularly rare events include blood abnormalities, severe allergic reactions, liver function abnormalities, and severe skin reactions, which require immediate consultation with healthcare professionals if symptoms appear. Since this medication suppresses gastric acid secretion, there may be a slight increase in the risk of bacterial infections in the stomach. Furthermore, long-term use may increase the risk of fractures, so periodic examinations are necessary for individuals at risk of osteoporosis. Long-term use of this medication can lead to hypomagnesemia, so regular blood tests are important, especially for those taking it for more than a year or taking medications that lower magnesium levels. This medication interacts with many other drugs, so it is necessary to consult a physician or pharmacist, especially if you are taking antibiotics, antiviral drugs, anticoagulants, or antiepileptic drugs. During pregnancy, data on the safety of this medication is limited, so it should be used cautiously if you are pregnant or planning to become pregnant. Nursing women are advised not to take this medication. In case of overdose, there is no specific antidote, so it is important to receive appropriate treatment according to the symptoms. This medication should be kept out of reach of children, and transferring it to another container is not advisable as it may affect quality.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fractures, arthralgia, myalgia, muscular weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, lethargy, pain, rigidity, peripheral edema, flushing, hypertension, tachycardia, thyroid enlargement, irritable bowel syndrome, worsening constipation, dyspepsia, dysphagia, gastrointestinal developmental disorder, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, glossitis, ulcerative stomatitis, otitis, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver function abnormalities, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, articular disease, seizures, fibromyalgia syndrome, hernia, rheumatic polymyalgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disorder, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, worsening asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papulovesicular rash, otitis media, olfactory abnormalities, loss of taste, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal pigmentation, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from exposure to air or moisture. It is recommended to maintain a storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pale pink, round film-coated tablet

Package unit

28 tablets (14 tablets/PTP*2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.